Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety, tolerability and immunogenicity of two RSV vaccine candidates, Ad26.RSV.FA2 followed by Ad35.RSV.FA2, in healthy adult …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection
• Respiratory Tract Infections

Drugs mentioned

• Ad26.RSV.FA2
• Ad35.RSV.FA2

Snippet

Sponsor: Crucell Holland BV | Conditions: Respiratory Syncytial Viruses, Respiratory Tract Infections | Phase 1 | Status: COMPLETED